{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T16:06:41Z","timestamp":1790179601358,"version":"4.1.0"},"reference-count":16,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,12,1]],"date-time":"2025-12-01T00:00:00Z","timestamp":1764547200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100000801","name":"Bayer HealthCare","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100000801","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100004326","name":"Bayer AG","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004326","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["The French Journal of Urology"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1016\/j.fjurol.2025.103009","type":"journal-article","created":{"date-parts":[[2025,10,17]],"date-time":"2025-10-17T10:22:09Z","timestamp":1760696529000},"page":"103009","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["A multidisciplinary approach to managing non-metastatic castration resistant prostate cancer: Insights from a national practice survey"],"prefix":"10.1016","volume":"35","author":[{"given":"Paul","family":"Sargos","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles","family":"Merlin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fran\u00e7ois","family":"Rozet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Myriam","family":"Chebbah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Solenn","family":"Le Clanche","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"St\u00e9phane","family":"Supiot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00e9raldine","family":"Pignot","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yann","family":"Neuzillet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.fjurol.2025.103009_bib0085","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J Clin"},{"key":"10.1016\/j.fjurol.2025.103009_bib0090","unstructured":"International Agency for Research on Cancer WHO. Globocan 2020 n.d."},{"key":"10.1016\/j.fjurol.2025.103009_bib0095","unstructured":"Institut National du Cancer. Le cancer de la prostate n.d. https:\/\/www.e-cancer.fr\/Professionnels-de-sante\/Les-chiffres-du-cancer-en-France\/Epidemiologie-des-cancers\/Les-cancers-les-plus-frequents\/Cancer-de-la-prostate (accessed January 3, 2024)."},{"key":"10.1016\/j.fjurol.2025.103009_bib0100","unstructured":"Lowrance W, Rodney B, Chou R, Chapin BF, Crispino T, Dreicer R, et al. Advanced Prostate Cancer: AUA\/SUO Guideline 2020; American Urological Association."},{"key":"10.1016\/j.fjurol.2025.103009_bib0105","unstructured":"Mottet N, Cornford P, van den Bergh RCN, Briers E, De Santis M, Gillessen S, et al. EAU-EANM-ESTRO-ESUR-ISUP-SIOG Guidelines On Prostate Cancer 2022 2022."},{"key":"10.1016\/j.fjurol.2025.103009_bib0110","doi-asserted-by":"crossref","first-page":"1119","DOI":"10.1016\/j.annonc.2020.06.011","article-title":"Prostate cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up","volume":"31","author":"Parker","year":"2020","journal-title":"Ann Oncol"},{"key":"10.1016\/j.fjurol.2025.103009_bib0115","first-page":"1288","article-title":"NCCN Guidelines\u00ae Insights: Prostate Cancer, Version 1.2023","volume":"20","author":"Schaeffer","year":"2022","journal-title":"J Natl Compr Canc Netw"},{"key":"10.1016\/j.fjurol.2025.103009_bib0120","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1007\/s40261-022-01178-y","article-title":"Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends","volume":"42","author":"Figueiredo","year":"2022","journal-title":"Clin Drug Investig"},{"key":"10.1016\/j.fjurol.2025.103009_bib0125","doi-asserted-by":"crossref","first-page":"e27","DOI":"10.1016\/j.clgc.2022.10.003","article-title":"Prevalence and Natural History of Non-metastatic Castrate Resistant Prostate Cancer: A Population-Based Analysis","volume":"21","author":"Hird","year":"2023","journal-title":"Clinical Genitourinary Cancer"},{"key":"10.1016\/j.fjurol.2025.103009_bib0130","unstructured":"Urofrance\/French AFU Cancer Committee Guidelines - Update 2022-2024: prostate cancer - Management of metastatic disease and castration resistance - Urofrance n.d. https:\/\/www.urofrance.org\/recommandation\/french-afu-cancer-committee-guidelines-update-2022-2024-prostate-cancer-management-of-metastatic-disease-and-castration-resistance\/.(accessed March 21, 2025)."},{"key":"10.1016\/j.fjurol.2025.103009_bib0135","unstructured":"Arr\u00eat\u00e9 du 9 mars 2020 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux. n.d."},{"key":"10.1016\/j.fjurol.2025.103009_bib0140","unstructured":"Arr\u00eat\u00e9 du 24 mars 2020 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux. n.d."},{"key":"10.1016\/j.fjurol.2025.103009_bib0145","unstructured":"Arr\u00eat\u00e9 du 5 mars 2021 modifiant la liste des sp\u00e9cialit\u00e9s pharmaceutiques remboursables aux assur\u00e9s sociaux. n.d."},{"key":"10.1016\/j.fjurol.2025.103009_bib0150","unstructured":"UNICANCER. Combination of Darolutamide and Stereotactic Body Radiation Therapy in Patients With Castration Resistant Prostate Cancer and Oligometastases on Functional Imaging. clinicaltrials.gov; 2024."},{"key":"10.1016\/j.fjurol.2025.103009_bib0155","doi-asserted-by":"crossref","first-page":"22","DOI":"10.1200\/JCO.2025.43.5_suppl.22","article-title":"Metastases-directed therapy in addition to standard systemic therapy in oligometastatic castration resistant prostate cancer: A randomized phase II trial (GROUQ-PCS 9)","volume":"43","author":"Niazi","year":"2025","journal-title":"JCO"},{"key":"10.1016\/j.fjurol.2025.103009_bib0160","doi-asserted-by":"crossref","first-page":"706","DOI":"10.1053\/j.semnuclmed.2023.02.006","article-title":"Histopathologically Validated Diagnostic Accuracy of PSMA-PET\/CT in the Primary and Secondary Staging of Prostate Cancer and the Impact of PSMA-PET\/CT on Clinical Management: A Systematic Review and Meta-analysis","volume":"53","author":"Jeet","year":"2023","journal-title":"Semin Nucl Med"}],"container-title":["The French Journal of Urology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001561?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2950393025001561?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,23]],"date-time":"2026-09-23T15:46:30Z","timestamp":1790178390000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2950393025001561"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,12]]},"references-count":16,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["S2950393025001561"],"URL":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103009","relation":{},"ISSN":["2950-3930"],"issn-type":[{"value":"2950-3930","type":"print"}],"subject":[],"published":{"date-parts":[[2025,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"A multidisciplinary approach to managing non-metastatic castration resistant prostate cancer: Insights from a national practice survey","name":"articletitle","label":"Article Title"},{"value":"The French Journal of Urology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.fjurol.2025.103009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"103009"}}